Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentasitol is a dietary supplement developed by Penta Pharma, specifically formulated to support women's reproductive health and address female infertility, particularly in the context of Polycystic Ovary Syndrome (PCOS). The supplement typically contains a combination of Myo-inositol and D-chiro-inositol, often in a physiologically relevant 40:1 ratio, which act as insulin sensitizers to help restore hormonal balance, improve ovulatory function, and enhance oocyte quality. Additionally, it includes Folic acid to support DNA synthesis and prenatal health. By modulating insulin signaling and reducing androgen levels, Pentasitol aims to increase the chances of conception and improve metabolic parameters in women with hormonal imbalances.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pentasitol.